Titan Pharmaceuticals (TTNP) Competitors $4.33 +0.07 (+1.62%) Closing price 07/2/2025 03:57 PM EasternExtended Trading$4.08 -0.25 (-5.73%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TTNP vs. PMN, GOVX, PRPH, ALLR, HOTH, LEXX, NKGN, CASI, SYBX, and EDSAShould you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Promis Neurosciences (PMN), GeoVax Labs (GOVX), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Hoth Therapeutics (HOTH), Lexaria Bioscience (LEXX), NKGen Biotech (NKGN), CASI Pharmaceuticals (CASI), Synlogic (SYBX), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry. Titan Pharmaceuticals vs. Its Competitors Promis Neurosciences GeoVax Labs ProPhase Labs Allarity Therapeutics Hoth Therapeutics Lexaria Bioscience NKGen Biotech CASI Pharmaceuticals Synlogic Edesa Biotech Promis Neurosciences (NASDAQ:PMN) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Do analysts recommend PMN or TTNP? Promis Neurosciences currently has a consensus price target of $4.50, indicating a potential upside of 904.46%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Titan Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Titan Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in PMN or TTNP? 50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. 6.1% of Promis Neurosciences shares are owned by insiders. Comparatively, 0.7% of Titan Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, PMN or TTNP? Promis Neurosciences has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Does the media prefer PMN or TTNP? In the previous week, Titan Pharmaceuticals had 5 more articles in the media than Promis Neurosciences. MarketBeat recorded 5 mentions for Titan Pharmaceuticals and 0 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 1.89 beat Titan Pharmaceuticals' score of 0.65 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Promis Neurosciences Very Positive Titan Pharmaceuticals Positive Is PMN or TTNP more profitable? Titan Pharmaceuticals' return on equity of -145.92% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Promis NeurosciencesN/A -186.19% -98.56% Titan Pharmaceuticals N/A -145.92%-129.20% Which has higher earnings & valuation, PMN or TTNP? Promis Neurosciences has higher earnings, but lower revenue than Titan Pharmaceuticals. Promis Neurosciences is trading at a lower price-to-earnings ratio than Titan Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPromis NeurosciencesN/AN/A$2.78M-$0.05-8.96Titan Pharmaceuticals$180K21.89-$4.71M-$4.59-0.94 SummaryPromis Neurosciences beats Titan Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Titan Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TTNP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TTNP vs. The Competition Export to ExcelMetricTitan PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.89M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.9421.3126.1719.90Price / Sales21.89278.47413.55113.66Price / CashN/A41.4736.1356.90Price / Book1.627.518.025.38Net Income-$4.71M-$55.05M$3.15B$248.50M7 Day Performance-0.51%2.07%1.48%2.06%1 Month Performance-9.25%4.84%3.66%4.86%1 Year Performance-17.70%5.37%34.68%20.24% Titan Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TTNPTitan Pharmaceuticals0.3167 of 5 stars$4.33+1.6%N/A-18.0%$3.89M$180K-0.9410PMNPromis Neurosciences3.6449 of 5 stars$0.48+0.7%$4.50+830.1%-73.0%$15.70MN/A-9.685Positive NewsGOVXGeoVax Labs3.7994 of 5 stars$0.87-9.8%$11.10+1,182.2%-85.6%$15.29M$3.95M-0.2410News CoverageGap UpPRPHProPhase Labs1.4779 of 5 stars$0.39+6.6%N/A-89.4%$15.25M$6.77M-0.31130ALLRAllarity Therapeutics1.1193 of 5 stars$1.01+1.0%N/A-84.6%$15.08MN/A0.0010News CoverageHOTHHoth Therapeutics1.8835 of 5 stars$1.17+3.5%$4.00+241.9%+35.9%$14.93MN/A-1.034LEXXLexaria Bioscience3.2302 of 5 stars$0.87+2.5%$7.00+704.6%-67.4%$14.91M$460K-1.477News CoverageAnalyst ForecastAnalyst RevisionNKGNNKGen BiotechN/A$0.33+37.4%N/A-75.2%$14.83MN/A-0.06N/AGap DownCASICASI Pharmaceuticals4.5898 of 5 stars$1.18-1.7%$4.00+239.0%-75.4%$14.76M$28.54M-0.46180News CoveragePositive NewsHigh Trading VolumeSYBXSynlogic1.0163 of 5 stars$1.27+2.4%N/A-15.7%$14.50M$10K-0.5180Gap UpEDSAEdesa Biotech1.7428 of 5 stars$2.03-1.0%$5.00+146.3%-51.5%$14.40MN/A-1.2820Positive NewsGap Up Related Companies and Tools Related Companies Promis Neurosciences Alternatives GeoVax Labs Alternatives ProPhase Labs Alternatives Allarity Therapeutics Alternatives Hoth Therapeutics Alternatives Lexaria Bioscience Alternatives NKGen Biotech Alternatives CASI Pharmaceuticals Alternatives Synlogic Alternatives Edesa Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TTNP) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
